Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
826 stopped studies mapped to Malignant Female Reproductive System Neoplasm and descendants · 86% state a reason
Over the 826 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06068738 | Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer(EXCYTE-1) | — | terminated | Oct 5, 2023 | Exscientia AI Limited | Study was terminated due to a strategic re-evaluation of the company's overall business and… | Sponsor / business decision |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With… | Phase 2 | withdrawn | Oct 25, 2023 | Nykode Therapeutics ASA | Trial VB-C-04 was stopped due to company strategic reasons and recent changes in standard of care… | Sponsor / business decision |
| NCT03493464 | BR55 in Characterization of Ovarian Lesions | Phase 2 | terminated | Apr 10, 2018 | Bracco Diagnostics, Inc | Sponsor decision; expiration of available study agent due to long recruitment timeline. | Enrollment / accrual |
| NCT03691376 | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan… | Phase 1 | terminated | Oct 1, 2018 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Phase 1 | withdrawn | Dec 19, 2022 | Brown University | Lack of accrual | Enrollment / accrual |
| NCT03644342 | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of…(NIVIX) | Phase 1 / Phase 2 | terminated | Aug 23, 2018 | Michelle S Ludwig | A recent change in treatment landscape may make study futile | Other (stated, no rule matched) |
| NCT04248153 | Optimal Timing of BR55 CEUS of the Ovaries | Phase 2 | terminated | Jan 30, 2020 | Bracco Diagnostics, Inc | Sponsor decision; expiration of available study agent due to long recruitment timeline. | Enrollment / accrual |
| NCT04849858 | Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic… | Phase 3 | terminated | Apr 19, 2021 | University of California, Irvine | Low recruitment | Enrollment / accrual |
| NCT01445275 | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who… | — | withdrawn | Oct 3, 2011 | Gynecologic Oncology Group | not stated | Not stated |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | Phase 1 / Phase 2 | terminated | Jan 8, 2009 | NantCell, Inc. | Sponsor decision - subjects rolled over to protocol 20101116 | Sponsor / business decision |
| NCT04377087 | Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent… | Phase 2 | terminated | May 6, 2020 | Sarah E Taylor | Slow enrollment | Enrollment / accrual |
| NCT06216561 | Intraperitoneal LSTA1 in CRS-HIPEC | Phase 1 | withdrawn | Jan 22, 2024 | University of California, San Diego | closed early due to low (0) accrual | Enrollment / accrual |
| NCT01199250 | Biomarkers in Samples From Patients With Endometrial Cancer | — | withdrawn | Sep 10, 2010 | Gynecologic Oncology Group | Not a treatment/applicable clinical trial | Other (stated, no rule matched) |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant… | Phase 1 / Phase 2 | terminated | Oct 3, 2023 | Tango Therapeutics, Inc. | Terminated due to safety | Safety / toxicity |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803… | Phase 1 / Phase 2 | terminated | Apr 25, 2017 | NantCell, Inc. | The study was terminated before any dose escalation occurred in order to pursue other studies… | Other (stated, no rule matched) |
| NCT03323398 | Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in… | Phase 1 / Phase 2 | terminated | Oct 27, 2017 | ModernaTX, Inc. | This study was halted prematurely because the efficacy endpoints were not met for either treatment… | Efficacy / futility |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT04408599 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid… | Phase 1 / Phase 2 | terminated | May 29, 2020 | NextCure, Inc. | Upon completion of the Phase 1 portion of the NC410 monotherapy trial, NextCure focused efforts on… | Other (stated, no rule matched) |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and… | Phase 2 | terminated | Feb 20, 2018 | M.D. Anderson Cancer Center | Project delays | Other (stated, no rule matched) |
| NCT03367871 | Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer | Phase 2 | terminated | Dec 11, 2017 | University of Miami | Investigator left institution | Investigator |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT04004884 | Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)(LISA) | — | terminated | Jul 2, 2019 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Lack of recruitment | Enrollment / accrual |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors… | Phase 1 | terminated | Jan 27, 2021 | Exelixis | Business reasons | Sponsor / business decision |
| NCT05107739 | A Study of DeTIL-0255 in Adults With Advanced Malignancies | Phase 1 | terminated | Nov 4, 2021 | Nurix Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT06046274 | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial… | Phase 2 | withdrawn | Sep 21, 2023 | Genmab | Enrollment challenged by availability of other treatment options | Enrollment / accrual |
| NCT04542603 | Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of… | Phase 1 | withdrawn | Sep 9, 2020 | University of Alabama at Birmingham | No recruitment/enrollment and funding expired. | Enrollment / accrual |
| NCT05538624 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma… | Phase 1 / Phase 2 | terminated | Sep 14, 2022 | Avenge Bio, Inc | Sponsor Decision to close study | Sponsor / business decision |
| NCT03128294 | Long Term Survivors in Ovarian Cancer | — | terminated | Apr 25, 2017 | University Medical Center Groningen | Data was not sufficiently complete and reliable for analysis (retrospective chart research) | Other (stated, no rule matched) |
| NCT05877404 | Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial… | — | terminated | May 26, 2023 | Wake Forest University Health Sciences | This was a national survey of physicians. Per the protocol, they were only allowed to be contacted… | Other (stated, no rule matched) |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in… | Phase 1 / Phase 2 | terminated | Oct 17, 2017 | Sumitomo Pharma America, Inc. | Sponsor's decision to terminate development of the program. | Sponsor / business decision |
| NCT04731441 | Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact | N/A | terminated | Feb 1, 2021 | Milton S. Hershey Medical Center | Difficulty enrolling and we lost exercise specialist | Enrollment / accrual |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT05390021 | PET/MRI in Endometrial Cancer | N/A | withdrawn | May 25, 2022 | Massachusetts General Hospital | Unable to enroll patients to study | Enrollment / accrual |
| NCT04743999 | Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage… | Phase 2 | terminated | Feb 8, 2021 | Henry Ford Health System | Low accrual | Enrollment / accrual |
| NCT05033132 | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in… | Phase 2 | withdrawn | Sep 2, 2021 | Agenus Inc. | Study was never initiated. | Other (stated, no rule matched) |
| NCT00889733 | Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer(OVHM-01) | Phase 1 / Phase 2 | terminated | Apr 29, 2009 | University Health Network, Toronto | Poor recruitment | Enrollment / accrual |
| NCT01962948 | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or… | Phase 1 / Phase 2 | terminated | Oct 16, 2013 | Fox Chase Cancer Center | Study drug is no longer supplied by grantor. | Other (stated, no rule matched) |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With… | Phase 1 | terminated | Dec 23, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Dec 31, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With… | Phase 1 | terminated | Oct 14, 2020 | Haihe Biopharma Co., Ltd. | Business decision | Sponsor / business decision |
| NCT02574442 | Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer(Confocal) | — | terminated | Oct 12, 2015 | British Columbia Cancer Agency | Funding has run out | Funding |
| NCT03285841 | OCT-AF Imaging of Pre-cancers of Vulva and Cervix | — | terminated | Sep 18, 2017 | British Columbia Cancer Agency | No funding | Funding |
| NCT04396340 | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to… | Phase 1 | terminated | May 20, 2020 | Mersana Therapeutics | discontinued development program | Other (stated, no rule matched) |
| NCT05215496 | [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer | Phase 1 | terminated | Jan 31, 2022 | Lioe-Fee de Geus-Oei, MD PhD | Reached the stop criteria after the interim analysis | Efficacy / futility |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With… | Phase 2 | terminated | Oct 5, 2016 | M.D. Anderson Cancer Center | The study was terminated early by the Sponsor | Other (stated, no rule matched) |
| NCT04102436 | Non-Viral TCR Gene Therapy | Phase 2 | withdrawn | Sep 25, 2019 | National Cancer Institute (NCI) | Difficulty with availability of GLP-grade reagents for manufacturing. | Drug supply |
| NCT05689359 | Evaluation of Hydroxychloroquine to Prevent CIPN | Phase 2 | withdrawn | Jan 19, 2023 | University of Arizona | Per Principal Investigator, it is not feasible to move forward with this trial. | Investigator |
| NCT04718376 | A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed… | Phase 1 | terminated | Jan 22, 2021 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT03345784 | Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper… | Phase 1 | terminated | Nov 17, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 26, 2024source: clinicaltrials